Here's my thought for the day to go with my link to FDA site.....
BMOD finished the trial last Summer. Finished their report. The FDA reviewed it and said you need to replace some of the 21 samples from the second cohort. The cancer in some of those 21 samples didn't originate in the lungs. The cancer started somewhere else in the body and spread to the lungs. Go replace those and come back to us.
The key point.....the FDA Pilot Phase II Cypath Report from BMOD's Clinical Investigators was already completed once....finished...written....Ready to go. Now they just have to go back into the old report and edit certain parts of it that related to the 21 samples they just replaced. Presto we have our Top line results. This is all going to start happening quickly now.
Market Data 
Markets 
AI
